Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProMune with or without dacarbazine in advanced melanoma
NCT00070642Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2003
- Primary completion
- Dec 2005
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
01
Overview
Phase 2, randomised, open-label trial of agatolimod in melanoma, sponsored by Pfizer. Primary endpoints: Overall Response Rate and Overall Survival. Started Dec 2003; status: completed.
02
Drugs
agatolimod
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00070642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070642.